Sensorimotor gating, which is severely disrupted in schizophrenic patients, can be measured by assessing prepulse inhibition of the acoustic startle response (PPI). Acute administration of D 2 -like receptor agonists such as quinpirole reduces PPI, but tolerance occurs upon repeated administration. In the present study, PPI in rats was reduced by acute quinpirole (0.1 mg/kg, s.c.), but not following repeated quinpirole treatment once daily for 28 days. Repeated quinpirole treatment did not alter the levels of basal-, forskolin-(5 mM), or SKF 82958-(10 mM) stimulated adenylate cyclase activity in the nucleus accumbens (NAc), but significantly increased cAMPdependent protein kinase (PKA) activity. Phosphorylation of cAMP response element-binding protein (CREB) was significantly greater in the NAc after repeated quinpirole treatment than after repeated saline treatment with or without acute quinpirole challenge. Activation of PKA by intra-accumbens infusion of the cAMP analog, Sp-cAMPS, prevented acute quinpirole-induced PPI disruption, similar to the behavioral effect observed following repeated quinpirole treatment. Thus, repeated quinpirole treatment increases NAc PKA activity and CREB phosphorylation, and this neuroadaptive response might facilitate the recovery of sensorimotor gating in schizophrenia.
INTRODUCTION
Deficits in sensorimotor gating that may lead to sensory flooding and cognitive fragmentation in patients with schizophrenia can be detected across species by quantifying prepulse inhibition of the acoustic startle response (PPI). Normally, forebrain processing of information contained within a prepulse stimulus can inhibit brain stem startle responses to a subsequent pulse stimulus. Several neurotransmitters and their respective receptors, including dopamine D 2 -like receptors in the nucleus accumbens (NAc), reduce PPI such that processing becomes disrupted (Wan and Swerdlow, 1993) .
Repeated treatment with indirect dopamine agonists, such as cocaine or amphetamine, attenuates PPI disruption (Byrnes and Hammer, 2000; Feifel et al, 2002) . Furthermore, PPI disruption induced by acute treatment with the D 2 -like receptor agonist, quinpirole, is completely reversed by longterm treatment (Culm and Hammer, 2004) , but the putative substrates underlying such PPI tolerance are poorly understood. The lack of effect of repeated quinpirole treatment on extracellular dopamine release in the NAc, however, suggests that postsynaptic neuroadaptation may occur (Koeltzow et al, 2003) .
Acute D 2 -like receptor stimulation reduces cAMP signaling by decreasing adenylate cyclase activity via G i /G o coupling (Gilman, 1987; Olianas and Onali, 1987) . Prolonged activation of such G i /G o -coupled receptors produces heterologous sensitization of cAMP signaling, as occurs in cultured neurons upon stimulation of opiate, a 2 -adrenergic, muscarinic, or adenosine receptors (reviewed by Thomas and Hoffman, 1987) , as well as following extended quinpirole exposure (Watts and Neve, 1996) . In contrast, D 2 -like receptor antagonist-induced Fos expression in striatopallidal neurons is dependent on phosphorylation of cAMP response element-binding protein (CREB; Konradi and Heckers, 1995; Robertson and Jian, 1995) . However, the selective effects of repeated D 2 -like agonist treatment have not been examined. Modulation of intracellular adenylate cyclase and cAMP-dependent protein kinase (PKA) influence a range of neuronal processes, including protein phosphorylation, regulation of ion channel conductance, and gene expression (for a review see Nestler, 2001 ). Thus, alteration of cAMP signaling after repeated D 2 -like agonist treatment might be associated with the elimination of sensorimotor gating deficits. In the present study, our goal was to assess molecular adaptations of cAMP signaling in the NAc induced by long-term treatment with quinpirole, a selective dopamine D 2 -like receptor agonist, in a paradigm that reverses sensorimotor gating deficits.
MATERIALS AND METHODS

Animals and Drug Treatment
In all of the following experiments, rats were provided with food and water ad libitum while housed in a climatecontrolled facility with a 12 h reverse light/dark cycle (lights off at 0900). Animals were allowed to acclimate to the laboratory for 7 days prior to handling. All experiments were approved by the Tufts-New England Medical Center Animal Care and Use Committee and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Male Sprague-Dawley rats (Charles River Laboratories, Kingston, RI) weighing 250-300 g were habituated to handling and subcutaneous (s.c.) saline injection, and placed into a Startle Monitor Behavioral Testing chamber (Hamilton Kinder; Poway, CA) with 70 dB ambient noise for 5 min daily on each of 2 days prior to baseline PPI testing. Starting 2-3 days later, animals were treated once daily for 28 consecutive days with quinpirole (0.1 mg/kg, s.c.; RBISigma, Natick, MA) or saline vehicle (1.0 ml/kg).
Prepulse Inhibition Testing
Startle amplitude was determined using the Startle Monitor Behavioral Testing System (Hamilton Kinder; Poway, CA) at baseline and after quinpirole administration on treatment days 1 and 28. Each animal was exposed to 70 dB ambient noise for 5 min followed by a test session consisting of the randomized presentation of 24 pulse trials (120 dB, 40 ms pulse), 30 prepulse trials (10 each 73, 76, and 82 dB, 20 ms prepulse given 100 ms prior to a 120 dB, 40 ms pulse) and 10 trials without pulse or prepulse presentation. The average intertrial interval was 15 s. The acoustic startle response to pulse trials during baseline testing was used to normalize animals into treatment groups such that each group yielded the same mean response to pulse trials. A piezoelectric accelerometer was used to measure response within the chamber. The first drug challenge test session began 10 min after quinpirole treatment. The percent PPI was calculated using the following equation: 100À((mean prepulse trial response/mean pulse trial response) Â 100). The percent prepulse inhibition at each prepulse level and mean pulse trial response data were analyzed using Wilcoxon's signedrank tests and the Wilcoxon's rank-sum tests with Bonferroni correction for multiple comparisons.
Sample Preparation: Adenylate Cyclase and PKA Assays
After 28 days of daily saline or quinpirole treatment, PPI was assessed as described above. Rats were challenged the following day with quinpirole, and were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and decapitated 25 min later. Brains were removed, frozen at À301C in 2-methylbutane and stored at À801C until the day of the assay. Adenylate cyclase and PKA assays were conducted as accomplished previously (Lu et al, 2003) , as modified from Terwilliger et al (1991) . Briefly, brains were sectioned using a À201C cryostat to a level corresponding to 1.7 mm anterior to bregma (Paxinos and Watson, 1997) . Bilateral 2 mm wide micropunches containing the entire NAc were obtained from 1 mm thick tissue slabs, and were sonicated in ice-cold sonication buffer consisting of 20 mM Tris (pH 7.4), 1 mM EDTA, 1 mM microcystin and protease inhibitors (1/2 tablet of Complete Mini peptidase inhibitors per 50 ml buffer; Roche Applied Science, Indianapolis, IN). The sample was centrifuged at 20 000g for 20 min at 41C. The supernatant was transferred into a fresh tube and stored at À351C for PKA assays. The resulting pellet was resuspended in 150 ml of AC buffer containing 20 mM Tris HCl (pH 7.4) and 1 mM EDTA for use in adenylate cyclase assays. Protein content in resuspended pellet fractions was calculated using a protein assay kit (BioRad, Hercules, CA).
Adenylate Cyclase Assays
Resuspended pellet samples were diluted to 0.02 mg/ml protein in AC buffer to determine forskolin-stimulated adenylate cyclase activity or diluted to 0.2 mg/ml to determine basal and SKF-82958-stimulated adenylate cyclase activity, and DTT was added to a final concentration of 1 mM. In a total volume of 100 ml, 25 ml of sample protein was mixed with (final concentrations) 50 mM triethanolamine HCl (pH 7.4), 0.1 mM EGTA, 2 mM MgCl 2 , 1 mM DTT, 1 mM isobutyl-methylxanthine, 0.2% bovine serum albumin (BSA), 50 mM GTP, and 5 mM forskolin (in 0.05% ethanol vehicle) or 10 mM SKF 82958. The assay tubes were incubated for 10 min at 301C before adding 5 ml of 1 mM ATP to start the reaction. The assays were terminated 5 min later by the addition of 0.4 ml of 0.125 M HCl and frozen at -351C. The next day, the amount of cAMP product in each assay tube was determined using the cAMP ELISA kit (DE-0355; R&D Systems; Minneapolis, MN) according to the instructions for assaying nonacetylated cAMP. A standard curve was utilized to express data in pmol of cAMP per mg of protein per min, and the data were compared using unpaired Student's t-tests.
PKA Activity Assays
Supernatants from the samples were diluted to 0.6 mg/ml protein in sonication buffer, and DTT was added to a final concentration of 1 mM. In a total volume of 55 ml, 3 mg of sample protein was mixed with (final concentrations) 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA, 10 mM MgCl 2 , 0.05% NP-40 (Sigma-Aldrich, St Louis, MO), 10 mM DTT, 15 mg histone f2b (Sigma-Aldrich, St Louis, MO), 50 mM 32 P-labeled ATP (50 mCi/ml; 1 mCi/nmol), and either 1 mM of the PKA activator, 8-bromo-cAMP or 0.1 mg/ml of the PKA inhibitor (PKI; Sigma-Aldrich, St Louis, MO). The addition of PKI to the assay completely blocks 8-Br-cAMP-induced PKA activity. All samples were run in duplicate. Reactions started with the addition of 1.0 mCi/assay of [g-32 P]ATP and were carried out at room temperature for 3 min. Aliquots (25 ml) were spotted onto Whatman P81 filter paper (2 Â 2 cm 2 ), which was subsequently washed in distilled water and air-dried. The amount of [g-32 P] was quantified by liquid scintillation spectrometry. Total PKA activity was determined in the presence of 8-Br-cAMP (5 mM, PKA activator; Sigma-Aldrich, St Louis, MO), while nonspecific kinase activity was determined in the presence of PKI (0.1 mg/ml, PKA inhibitor; SigmaAldrich, St Louis, MO). PKA activity was calculated by subtracting nonspecific kinase activity from total kinase activity. Data were expressed as pmol of ATP transferred per mg of sample protein per min and compared using an unpaired Student's t-test.
Immunohistochemistry
Immunohistochemistry was performed on tissues isolated from additional rats treated once daily for 28 days with quinpirole (0.1 mg/kg, s.c.) or saline vehicle. On the 29th day, those treated repeatedly with saline were challenged with either quinpirole (0.1 mg/kg, s.c.) or saline vehicle, while those treated repeatedly with quinpirole were challenged with quinpirole (0.1 mg/kg, s.c.). At 25 min after the final saline or quinpirole challenge on the 29th day, sodium pentobarbital (100 mg/kg, i.p.) was administered and rats were transcardially perfused with ice-cold 4% paraformaldehyde, brains were removed and transferred onto graded sucrose supplemented with 50 mM NaF, then stored at 41C for less than 1 week prior to sectioning. Using a sliding microtome, 20 mm sections starting at 1.7 mm anterior to Bregma were collected in 50 mM Tris HCl (pH 7.4) containing 50 mM NaF. Sections were mounted onto Fisher SuperFrost Plus microscope slides, air-dried for 30 min and stored at À351C prior to immunohistochemical processing.
Phospho-CREB was detected using a polyclonal antibody specific for CREB only when phosphorylated at serine 133. Total CREB labeling was detected using a polyclonal antibody specific for CREB independent of phosphorylation state. Tissue sections were incubated for 1 h at 231C in 3% BSA and 0.4% Triton X in 0.1 M potassium phosphatebuffered saline followed by either a 16 h incubation with phospho-CREB antisera (1 : 500; Cell Signaling Technology, Beverly, MA) or a 48 h incubation with CREB antisera (1 : 1250; Cell Signaling Technology, Beverly, MA) at 41C. Sections were incubated in goat anti-rabbit secondary antiserum for 1 h followed by avidin-biotin-peroxidase reagents (Elite Vectastain Kit; Vector Laboratories, Burlingame, CA) for 45 min at 231C, and chromagen development in 0.33% NiCl 2 /0.05% DAB/0.03% H 2 O 2 in 100 mM Tris HCl for 5 min. Some tissue sections were incubated in the same antisera preadsorbed with phospho-CREB blocking peptide (1 : 10; Cell Signaling Technology, Beverly, MA).
The number of immunostained profiles within the NAc core located adjacent and dorsomedial to the anterior commissure, the central portion of the NAc shell, as well as medial and lateral regions of the caudatoputamen in sections located approximately 1.6 mm anterior to Bregma was determined using Image Pro Plus analysis software (v. 4.1.0.0, Media Cybernetics; Carlsbad, CA). Sample areas (49 000 mm 2 in size) were digitized from three to five sections per brain using a Cool Snap Pro video camera on an Olympus BH-2 microscope. In order to reduce background staining in the analysis, the mean intensity in cellfree regions was measured across all experimental tissues, and this background level was subtracted to eliminate nonspecific labeling in each section. A density threshold was applied across all experimental tissues and the number of immunoreactive nuclear profiles above this threshold was determined by the software. In order to exclude partial profiles, only those larger than 500 square pixels but smaller than 1500 square pixels were included. Data from each brain region were analyzed using a one-way analysis of variance followed by Student-Newman-Keuls post hoc test to determine the locus of main effects.
Infusion of PKA Activator
An additional series of rats received bilateral guide cannulas directed at the NAc (AP: þ 0.17 mm anterior to bregma; ML: 70.30 mm; and DV: À5.3 mm from dura mater; Paxinos and Watson, 1997) . Dummy cannulas were inserted to maintain patency. Baseline PPI was determined as described above both prior to stereotaxic surgery and after 1 week recovery to normalize groups and ensure that PPI level was unaffected by surgery. Starting 1 week later, injection cannulas extending 1 mm beyond the guide cannula were inserted into the NAc. The PKA activator, 8-bromo-adenosine 3 0 , 5 0 -cyclic monophosphorothiote (Sp-cAMPS, 80 nmol in 1 ml per side; Calbiochem, San Diego, CA), or saline vehicle was infused over a 5 min period utilizing a motorized syringe pump. After 30 min, at a time when Sp-cAMPS infusion into the NAc is maximally effective (Self et al, 1998) , animals received quinpirole (0.1 mg/kg, s.c.) or saline vehicle, followed 10 min later by PPI testing as described above. On four separate occasions 3-4 days apart, each rat received either intracranial SpcAMPS or vehicle with acute challenge of quinpirole, or intracranial Sp-cAMPS or vehicle with acute challenge of saline; the order of trials was counterbalanced to eliminate possible pretreatment effects. Data were analyzed using a Kruskal-Wallis analysis of variance with repeated measures followed by Bonferroni post hoc comparison. Following these experiments, brains were removed and the location of the injection cannula tip was determined.
RESULTS
PPI Recovery after Repeated Quinpirole Administration
Acute treatment with quinpirole significantly reduced PPI following 73, 76, or 82 dB prepulses by 16, 18, and 14%, respectively compared to vehicle treatment (Figure 1 ). After 28 days of repeated quinpirole administration, PPI significantly increased compared to day 1 treatment levels, indicating that a complete recovery of PPI occurred with repeated D 2 -like receptor agonist treatment. Neither mean acoustic startle response to pulse trials (Table 1) nor responses in the presence of ambient noise only (data not shown) were altered by acute or repeated quinpirole treatment.
Adaptations in cAMP Signaling after Repeated Quinpirole Treatment
Quinpirole challenge after repeated quinpirole treatment had no effect on basal adenylate cyclase activity compared to quinpirole challenge after saline treatment (acute: 86.876. 0 pmol/mg/min; repeated: 90.876.8 pmol/mg/min; Figure 2 ). Adenylate cyclase activity measured using forskolin (5 mM) was also unaffected by quinpirole treatment (acute: 530.4770.4 pmol/mg/min; repeated: 498775.2 pmol/mg/min). Furthermore, when dopamine D 1 -like receptors were stimulated with SKF 82958 (10 mM), no difference in cAMP accumulation was observed between treatment groups (acute: 172.3712.5 pmol/mg/min; repeated: 185.978.8 pmol/mg/min).
The effect of long-term quinpirole treatment on signaling was further characterized by assessing PKA activity. In cytosolic NAc fractions, PKA activity increased significantly by 66% upon quinpirole challenge after repeated quinpirole (repeated; n ¼ 5) treatment compared to quinpirole challenge following repeated saline (acute; n ¼ 6) treatment (acute: 1299.07254.3 pmol/mg/min; repeated: 2156.77170.5 pmol/mg/min; pp0.05).
Immunohistochemical data revealed that the phosphorylation state of CREB was altered by repeated quinpirole treatment in the NAc, but not in the caudatoputamen. Phospho-CREB labeling was quite low in the NAc upon acute quinpirole challenge (Figure 3a) , exhibiting slightly lower levels in the NAc core and shell compared to vehicle treatment (Figure 4) . In contrast, the number of phospho-CREB-like immunoreactive profiles in both regions of the NAc increased significantly upon quinpirole challenge after repeated quinpirole treatment compared to repeated saline treatment with or without acute quinpirole challenge (Figures 3b and 4) . For example, repeated quinpirole treatment increased phospho-CREB labeling in the NAc core 2.5-fold compared to repeated saline treatment and nearly 3.5-fold compared to acute quinpirole treatment. However, repeated quinpirole treatment had no significant effect on the number of phospho-CREB-like immunoreactive profiles in either medial or lateral caudatoputamen (Figures 3c, d  and 4 ). In fact, no phospho-CREB labeling above threshold density was present in the caudatoputamen f ollowing repeated quinpirole treatment (Figure 4) . Selectivity of labeling for phospho-CREB was confirmed by complete elimination of labeling after preadsorption (data not shown). Finally, the total number of NAc neurons expressing CREB protein compared to vehicle treatment was unchanged after repeated quinpirole treatment (Table 2) . Figure 1 Complete recovery of PPI occurs after 28 days repeated quinpirole treatment. Quinpirole was administered once daily and the effect of drug treatment on PPI was assessed on days 1 and 28. The percent PPI (mean7SEM) was calculated from data obtained using prepulses 3, 6, or 12 dB above ambient noise level (70 dB). Each treatment group contained 18 animals. *Significant (po0.05) difference compared to same day PPI in vehicle group. w Significant (po0.05) difference compared to day 1 PPI after quinpirole treatment. Figure 2 Repeated quinpirole treatment does not alter NAc adenylate cyclase activity. Adenylate cyclase activity was determined by measuring cAMP accumulation following forskolin (5 mM, using 0.5 mg protein in the assay; n ¼ 9 per group) or SKF 82958 (10 mM, using 5.0 mg protein in the assay; n ¼ 7 per group) stimulation. Data (mean7SEM) are expressed as the percent of acute treatment. Open bars: repeated saline followed by quinpirole challenge; solid bars: repeated quinpirole followed by quinpirole challenge.
PKA Activation and Quinpirole-Induced PPI Disruption
Histological examination confirmed that all injection cannulas targeted the central NAc, midway between the NAc core and shell. Infusions therefore affected both NAc core and shell. Systemic quinpirole treatment significantly reduced PPI following 73, 76, and 82 dB prepulses ( Figure 5 ). Infusion of Sp-cAMPS alone into the NAc produced a slight reduction of PPI, which was significant only after 76 dB prepulses. Nevertheless, infusion of Sp-cAMPS into the NAc prevented quinpirole-induced PPI disruption at all prepulse levels.
DISCUSSION
Repeated treatment with the selective D 2 -like receptor agonist, quinpirole, reversed the PPI deficit induced by acute quinpirole. Stimulation of D 2 -like receptors disrupts PPI via coupling to G ai /G ao proteins in the NAc (Culm et al, 2003) , implicating the involvement of adenylate cyclase and PKA in this brain region. However, repeated quinpirole Repeated quinpirole treatment induces phospho-CREB in the NAc core and shell, but not in the caudatoputamen. Rats were treated with quinpirole or saline vehicle for 28 days. The following day, saline-treated rats received quinpirole (acute quinpirole) or saline (repeated saline) challenge, while quinpirole-treated rats received quinpirole (repeated quinpirole) challenge prior to processing for phospho-CREB immunohistochemistry. Data are expressed as the number of nuclear profiles (mean7SEM) per mm 2 with greater than a fixed threshold density value. Treatment groups contain seven to eight animals. *Significant (po0.05) difference compared to vehicle and acute treatment; NAc ¼ nucleus accumbens; CP ¼ caudatoputamen; pCREB ¼ phospho-CREB.
treatment at the dose used herein does not alter G protein level or function in the NAc, despite complete reversal of the PPI deficit induced by acute quinpirole (Culm and Hammer, 2004) . The data reveal that repeated quinpirole treatment did not alter adenylate cyclase activity, having no effect on basal, forskolin-stimulated or D 1 -like agoniststimulated cAMP accumulation (Figure 2 ), although only single concentrations of forskolin and SKF 82958 were utilized. Our results in the intact brain, however, differ from the results of an in vitro study where prolonged (ie 2 h) stimulation of D 2 -like receptors by quinpirole increased adenylate cyclase activity (Watts and Neve, 1996) .
Adenylate cyclase activity was unaffected by repeated quinpirole administration despite a significant increase in PKA activity. This suggests that the same level of cAMP might differentially affect PKA due to enhanced activity or amount of the latter enzyme in the NAc. Such enhanced PKA activity following repeated quinpirole treatment could underlie increased phospho-CREB expression in the NAc (Figures 3 and 4) . However, PKA is only one of several kinases known to phosphorylate CREB. For example, protein kinase B/Akt, protein kinase C, and Ca 2 þ /calmodulin-dependent protein kinase all are implicated in quinpirole-mediated phosphorylation of CREB (BramiCherrier et al, 2002; Yan et al, 1999) . Thus, repeated quinpirole treatment can lead to phosphorylation of CREB in various ways, which might explain why phospho-CREB labeling in the NAc increased more than twice as much as NAc PKA activity after repeated quinpirole treatment.
Increased PKA Activity in the NAC Attenuates PPI Disruption PKA activation produced by infusion of Sp-cAMPS into the NAc prevents quinpirole-induced PPI disruption, although PPI returns to the level observed after vehicle treatment only after 82 dB prepulses ( Figure 5 ). Such local PKA activation affects all NAc core and shell efferent neurons, including both those that express predominantly D 1 -like receptors and those that express D 2 -like receptors (Robertson and Jian, 1995) . D 1 -like receptor stimulation is necessary but not sufficient to produce PPI disruption, except at the highest doses of agonist (Swerdlow et al, 2000) , although it can enhance disruptive effects of D 2 -like receptor stimulation (Wan et al, 1996) . Thus, activation of PKA in NAc neurons that express predominantly D 1 -like receptors might potentiate disruption, thereby limiting the action of Sp-cAMPS on D 2 -like receptor-expressing neurons to reverse quinpirole-induced PPI disruption. Nevertheless, the attenuation of PPI disruption produced by PKA activation in the NAc suggests that enhanced NAc PKA signaling underlies the reversal of sensorimotor gating deficits following repeated quinpirole treatment.
We observed that repeated quinpirole treatment induced phospho-CREB labeling in both NAc core and shell neurons, with slightly more induction present in the NAc core (Figure 4 ). The NAc core is somewhat more sensitive to acute quinpirole-induced PPI disruption (Wan et al, 1994) , perhaps because D 2 -like receptor density is greater in the NAc core than the shell (Bardo and Hammer, 1991) . The concurrence of PPI tolerance with phospho-CREB induction selectively in the NAc implicates CREB in the regulation of sensorimotor gating. CREB is a major transcription factor associated with memory and learning as well as with molecular and behavioral adaptations after long-term drug administration (Duman, 2002) . Long-term experimental alteration of CREB function in the NAc has been shown to alter behavior. For example, overexpression of dominantnegative mutant CREB, in which a substitution of serine 133 by alanine prevents CREB phosphorylation and inhibits endogenous CREB function, augments responses to anxiogenic or nociceptive stimuli (Barrot et al, 2002) , elicits an antidepressant response (Newton et al, 2002) , and increases the rewarding effect of cocaine (Carlezon et al, 1998) . In contrast, overexpression of CREB in the NAc diminishes an animal's response to anxiogenic or nociceptive stimuli (Barrot et al, 2002) and reduces the rewarding effect of cocaine (Carlezon et al, 1998) . Thus, CREB activation in the NAc following repeated quinpirole treatment might affect gene expression to promote PPI recovery.
Several nucleotide sequence variants have been identified in the promoter region of the CREB gene that might contribute to susceptibility to schizophrenia, especially involving cognitive symptoms (Kawanishi et al, 1999) . Furthermore, haloperidol or eticlopride treatment induce CREB phosphorylation (Pozzi et al, 2003) and increase PKA activity (Dwivedi et al, 2002) in striatum. Thus, neuroadaptation in response to repeated quinpirole treatment may produce antipsychotic-like effects on PKA and CREB in NAc efferent neurons. The regional selectivity of repeated quinpirole effects in the ventral striatum, then, might obviate the development of extrapyramidal side effects mediated by the dorsal striatum. Activated CREB stimulates transcription of various genes containing a cAMP response element in their promoter region, including serotonin 2A receptors, tyrosine hydroxylase, and others implicated in schizophrenia. Long-term D 2 -like receptor agonist therapy Figure 5 PKA activation in the NAc prevents acute quinpirole-induced PPI disruption. Intracranial Sp-cAMPS or vehicle administration occurred 30 min prior to systemic quinpirole or vehicle treatment. PPI testing was initiated 10 min after systemic challenge. The percent PPI (mean7SEM) was calculated from data obtained using prepulse levels 3, 6, or 12 dB above ambient noise level (70 dB). Treatment groups contain four to 16 animals. *Significant (po0.05) difference compared to intracranial and systemic vehicle treatment.
might thereby alter endogenous mechanisms mediating PPI disruption to facilitate recovery of sensorimotor gating in schizophrenia and in other neuropsychiatric disorders manifesting altered PPI. In fact, clinical research studies utilizing D 2 -like receptor agonists such as talipexole, roxindole, and pramipexole have demonstrated mild improvement, particularly in negative symptoms of schizophrenia (Benkert et al, 1995; Kasper et al, 1992; Ohmori et al, 1993) , while aripiprazole, a D 2 -like receptor partial agonist and serotonin 2A receptor antagonist, is effective for both positive and negative symptoms (Potkin et al, 2003) . The compensatory mechanisms described herein might underlie, in part, the clinical efficacy of D 2 -like receptor agonist therapy for schizophrenia.
